龙芳婷,梅 峰

液体超载在腹膜透析(peritoneal dialysis，PD)患者中很常见，进而导致心血管事件发生率和病死率增高。充分的液体清除是PD治疗的重要靶目标。传统的腹透液为葡萄糖，而葡萄糖不是理想的腹透液。艾考糊精腹透液作为一种新型腹透液，应用于腹膜透析的长保留阶段并形成有效的超滤，每日较传统葡萄糖腹透液获得更多净超滤量，从而改善液体超载PD患者的预后。本文旨对艾考糊精应用于PD液体超载患者中的研究进展作一综述。

艾考糊精；腹膜透析；超滤；液体超载

[1] Liu T,Zhao D,Huang J,et al.Research hotspots and development trends in volume management of peritoneal dialysis patients: a bibliometrics and visual analysis up to 2022.Int Urol Nephrol.2023 Nov 22. [2] Wang AY,Dong J,Xu X,et al.Volume management as a key dimension of a high-quality PD prescription. Perit Dial Int.2020 May;40(3):282-292. [3] Zheng S,Auguste BL.Five Things to Know About Volume Overload in Peritoneal Dialysis.Can J Kidney Health Dis.2023 Jan 20;10:20543581221150590. [4] Vrtovsnik F,Verger C,Van Biesen W,et al.The impact of volume overload on technique failure in incident peritoneal dialysis patients. Clin Kidney J. 2019 Dec 22;14(2):570-577. [5] Hsiao YA,Tian YC,Yen TH,et al.Ultrafiltration in patients on automated peritoneal dialysis with Homechoice Claria connected to Sharesource: A pilot study. Clin Nephrol.2022 Dec;98(6):274-279. [6] Nataatmadja MS,Johnson DW,Pascoe EM,et al.Associations Between Peritoneal Glucose Exposure, Glucose Degradation Product Exposure, and Peritoneal Membrane Transport Characteristics in Peritoneal Dialysis Patients: Secondary Analysis of the balANZ Trial.Perit Dial Int.2018 Sep-Oct;38(5):349-355. [7] Davies S,Zhao J,Mccullough KP,et al.International Icodextrin Use and Association with Peritoneal Membrane Function,Fluid Removal,Patient and Technique Survival.Kidney360.2022 Mar 1;3(5):872-882. [8] Goossen K,Becker M,Marshall MR,et al.Icodextrin Versus Glucose Solutions for the Once-Daily Long Dwell in Peritoneal Dialysis: An Enriched Systematic Review and Meta-analysis of Randomized Controlled Trials.Am J Kidney Dis.2020 Jun;75(6):830-846. [9] Morelle J,Stachowska-Pietka J,Öberg C,et al.ISPD recommendations for the evaluation of peritoneal membrane dysfunction in adults:Classification, measurement, interpretation and rationale for intervention.Perit Dial Int. 2021 Jul;41(4):352-372. [10] Morelle J,Marechal C,Yu Z,et al.AQP1 Promoter Variant,Water Transport, and Outcomes in Peritoneal Dialysis. N Engl J Med.2021 Oct 21;385(17):1570-1580. [11] Morelle J,Sow A,Fustin CA,et al.Mechanisms of Crystalloid versus Colloid Osmosis across the Peritoneal Membrane. J Am Soc Nephrol.2018 Jul;29(7):1875-1886. [12] Wang IK,Lin CL,Chen HC,et al.Risk of new-onset diabetes in end-stage renal disease patients undergoing dialysis: analysis from registry data of Taiwan. Nephrol Dial Transplant.2018 Apr 1;33(4):670-675. [13] De Moraes TP,Andreoli MC,Canziani ME,et al.Icodextrin reduces insulin resistance in non-diabetic patients undergoing automated peritoneal dialysis: results of a randomized controlled trial (STARCH). Nephrol Dial Transplant. 2015 Nov;30(11):1905-11. [14] Ng JK,Chan GC,Li PK.Icodextrin in Peritoneal Dialysis: Implications on Clinical Practice and Survival Outcome. Kidney360.2022 Apr 19;3(5):793-795. [15] Gensberger-Reigl S,Weigel I,Stützer J,et al.Degradation and de novo formation of nine major glucose degradation products during storage of peritoneal dialysis fluids.Sci Rep.2022 Mar 11;12(1):4268. [16] Krediet RT,Parikova A.Glucose-induced pseudohypoxia and advanced glycosylation end products explain peritoneal damage in long-term peritoneal dialysis.Perit Dial Int.2024 Jan;44(1):6-15. [17] 阳晓,严骏飞,余学清.艾考糊精腹透液的临床优势及获益人群[J].中华肾脏病杂志,2021,37(6):528-533. [18] 郭红霞,唐雯.新型腹膜透析液的研究进展[J].中国血液净化,2020,19(06):403-405+409. [19] Yang JY, Chen L, Peng YS, et al. Icodextrin Is Associated with a Lower Mortality Rate in Peritoneal Dialysis Patients. Perit Dial Int.2019 May-Jun;39(3):252-260. [20] Li PK, Chow KM, Cho Y, et al.ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int.2022 Mar;42(2):110-153. [21] 郭静,阳晓,毛海萍,等.艾考糊精透析液治疗腹膜透析相关性腹膜炎3例及文献复习[J].中华肾脏病杂志,2022,38(10):921-923. [22] Ng CH,Ong ZH,Sran HK,et al.Comparison of cardiovascular mortality in hemodialysis versus peritoneal dialysis.Int Urol Nephrol.2021 Jul;53(7):1363-1371. [23] Wang Y,Huang G,Ma X,et al.A retrospective study of baseline peritoneal transport character and left ventricular hypertrophy in incident peritoneal dialysis patients: interrelationship and prognostic impacts.Ren Fail.2022 Dec;44(1):2073-2084. [24] Park WY,Park S, Kim YW,et al.Clinical efficacy of biomarkers for evaluation of volume status in dialysis patients. Medicine (Baltimore).2020 Jul 31;99(31):e21460. [25] Vongsanim S,Davenport A.Factors associated with systolic hypertension in peritoneal dialysis patients.J Nephrol.2020 Apr;33(2):365-370. [26] Wang IK,Tsai TH,Chang SS,et al.Icodextrin is associated with a lower risk of atrial fibrillation in peritoneal dialysis patients.Nephrology (Carlton).2019 Dec;24(12):1273-1278. [27] Wang IK,Lin CL,Yen TH,et al.Icodextrin reduces the risk of congestive heart failure in peritoneal dialysis patients.Pharmacoepidemiol Drug Saf.2018 Apr;27(4):447-452. [28] Oba I,Shinozaki M,Harada K,et al.Icodextrin-based continuous ambulatory peritoneal dialysis therapy effectively reduces left ventricular mass index and protects cardiac function in patients with end-stage renal disease.Adv Perit Dial.2013;29:14-8. [29] Sanchez JE,Ulloa C,Bueno CM,et al.Impact of peritoneal dialysis strategy on technique and patient survival.Clin Kidney J.2023 Jul 3;16(12):2523-2529. [30] Yoon HE,Chang YK,Shin SJ,et al.Benefits of a continuous ambulatory peritoneal dialysis (CAPD) technique with one icodextrin-containing and two biocompatible glucose-containing dialysates for preservation of residual renal function and biocompatibility in incident CAPD patients.J Korean Med Sci.2014 Sep;29(9):1217-25. [31] Chang TI,Ryu DR,Yoo TH,et al.Effect of Icodextrin Solution on the Preservation of Residual Renal Function in Peritoneal Dialysis Patients:A Randomized Controlled Study.Medicine (Baltimore).2016 Mar;95(13):e2991.

点击下载PDF